Thomas Pincez: Emerging Challenges in Sickle Cell Disease Gene Therapy and Cancer Risk
Thomas Pincez, Adjunct Professor at McGill University, Assistant Professor at University of Montreal, Clinician-Scientist at Azrieli Research Centre of CHU Sainte-Justine, shared a post on LinkedIn about recent articles he and his colleagues co-authored, adding:
“Two reviews on current sickle cell disease challenges: Gene therapy and Cancer risk.
Thanks for this great work within RED.”
Title: The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care
Authors: Magalie Tardif, Manon Saby, Stéphanie Forté, Thomas Pincez
Read the Full Article on Cells.

Title: Should Sickle Cell Disease Be Considered a Cancer Predisposition Syndrome?
Authors: Elise Casadessus, Yves Pastore, Thomas Pincez
Read the Full Article on Children.

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 15:23Akshat Jain: 5 Key Clinical Takeaways from ISTH 2026
-
Jul 13, 2026, 15:15Alfonso J. Tafur: Insights on Periprocedural DOAC Management in Atrial Fibrillation at
-
Jul 13, 2026, 14:42Bruno Pougault: The Global Momentum Behind Innovation in Thrombosis and Hemostasis
-
Jul 13, 2026, 14:34Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026
-
Jul 13, 2026, 13:57Heghine Khachatryan: The Diagnostic Dilemma of Non-Criteria Obstetric APS
-
Jul 13, 2026, 13:49Mitra Najafi: Translating Years of Innovation into Global Scientific Dialogue at ISTH 2026
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026